Increasing prevalence of metabolic diseases is alarming and highlights the need for more effective and safer therapies. Current recommendations for therapy for metabolic syndrome focus on corrections of the individual components. Fibrates are used to treat hyperlipidemia as a predisposing factor to metabolic syndrome and cardiovascular disease. Fibrates mediate their therapeutic effects through the peroxisome proliferator-activated receptor alpha (PPARα). PPARα acts as a transcriptional activator of genes involved in lipolysis and ketone body synthesis. The majority of PPARα effects are mediated by recently discovered starvation hormone - fibroblast growth factor FGF21. Recent evidence from several animal studies indicates that FGF21 induces numerous beneficial metabolic changes without apparent adverse effects. These results suggest that FGF21 could be a novel and attractive drug candidate for the treatment of cardiovascular disease, obesity, and type 2 diabetes.
|Translated title of the contribution||Fasting hormone fibroblast growth factor 21 - New therapy for obesity and metabolic syndrome?|
|Number of pages||4|
|State||Published - Nov 1 2009|
- Metabolic syndrome
- Type 2 diabetes
ASJC Scopus subject areas
- Pharmaceutical Science